BioAdvance Capital
BioAdvance Capital is an evergreen fund focused on investing in early-stage life-science companies that have the potential to enhance human well-being and quality of life. With a long-term investment perspective, BioAdvance primarily targets companies in the Mid-Atlantic region. Their portfolio companies have collectively attracted over $4.2 billion in external capital to support their growth.
BioAdvance Capital
Portfolio
Holds a game-changing platform exploiting protein-conformation dynamics to discover next generation GPCR drugs devoid of on-target side effects.
#Biotechnology
Develops and commercializes sensor-based technologies and platform to improve medication adherence and care coordination in respiratory care.
#Healthcare Technology
Offers an AI-assisted virtual alternative to rehabilitative care for patients with cardiac and pulmonary-related diagnoses.
#Healthcare Technology
RNAimolecule to treat macular degeneration. Merged into Opko Health, Inc. in 2007.
#Biotechnology
Providing the allogeneic human Trophoblast Stem Cell (TSC) platform as the ideal starting cell source for cell and gene therapy.
#Biotechnology
Therapeutics and vaccines (CDX-110) against novel, proprietary cancer targets. Acquired by Celldex Therapeutics in 2005.
#Biotechnology
Novel imaging agent to detect amyloid plaque in patients with Alzheimer’s disease. Acquired by Eli Lilly and Company in 2010.
#Biotechnology
Developing a biologic therapy to promote synaptogenesis and directly affect vision loss in patients with dryAMD.
#Biotechnology
Creates 3D printers and bioinks for biologics/tissue regeneration for academic research and drug discovery applications.
#Biotechnology
Developed a proprietary gel formulation for the treatment of early stage mycosis fungoides. Approved by the FDA in 2013 and acquired by Actelion.
#Biotechnology
Developing novel, first-in-class, non-immunosuppressive therapies to treat chronic gastrointestinal conditions.
#Biotechnology
Developing a new approach to inhibition of CDK4 to limit resistance in metastatic breast cancer therapies.
#Biotechnology
Harnessing the regenerative properties of amniotic fluid and membrane to heal human disease.
#Biotechnology
Developing small molecule inhibitors of a novel pathway to treat melanoma and other cancers.
#Biotechnology
Total joint resurfacing technology based on a proprietary synthetic cartilage. Exited through refinancing in 2011.
#Medical Devices
Novel spinal nucleus replacement implants for degenerative disc disease. Acquired by Synthes, Inc. in 2004.
#Medical Devices
Commercializing the Horizon – a high throughput biopharmaceutical quality control tool.
#Biotechnology
Developing novel treatments and prevention methods for food allergy utilizing the tolerogenic immune system.
#Biotechnology
Delivers SaaS data-driven care quality and cost-efficiency solutions to payers, providers, and partners.
#Healthcare Technology
Developing novel therapies for the treatment of Alzheimer’s, Parkinson’s, and other neurodegenerative diseases.
#Biotechnology
Developing a specialty decision-making SaaS solution for improving outcomes and lowering the cost of treating chronic inflammatory disease.
#Healthcare Technology
Developing therapies to treat rare, life-threatening pulmonary diseases.
#Biotechnology
Employs an Adoptive Cell Therapy (ACT) approach to elicit tumor-specific T-cells for the treatment of solid tumors.
#Biotechnology
Focused on developing transformative gene therapy-based treatments for cardiovascular disease.
#Biotechnology
Provides hospitals and health systems with solutions for optimizing medication administration practices.
#Healthcare Technology
Rapid, Quantitative, Assay-based (RQA) test development and launch platform.
#Healthcare Technology
Leveraging expertise to identify unique tumor-specific targets for precision therapeutics.
#Biotechnology
Focused on the development of novel PARP inhibitors for cancer and neuroinflammatory conditions.
#Biotechnology
Developing therapeutics to catalyze effective immune responses in immunologically “cold” cancers.
#Biotechnology
Commercializing an FDA-approved handheld device to screen for intracranial bleeding.
#Medical Devices
Providing clinical drug supply management for global trials.
#Healthcare Services
Developing a pipeline of oncology products targeting pathways in cancer cells.
#Biotechnology
Developing allogeneic, gene modified cell therapies for cancer treatment.
#Biotechnology
Leader in topical drug delivery with a focus on viral conjunctivitis treatment.
#Biotechnology
Pioneering antagonists of the retinoid nuclear receptor pathway for cardiometabolic diseases and cancer.
#Biotechnology
Developing a pumped breast milk management system for Neonatal ICUs.
#Healthcare Technology